• Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
    • Green biotechnology
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
  • Team
    • Team
    • Collaborations
  • Insights
  • Work
    • Publications
    • Cases
  • Careers
  • Contact
  • Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
    • Green biotechnology
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
  • Team
    • Team
    • Collaborations
  • Insights
  • Work
    • Publications
    • Cases
  • Careers
  • Contact
  • You are here:
  • Home
  • Insights
  • Assessing cosmetic ingredients for endocrine disrupting properties

Assessing cosmetic ingredients for endocrine disrupting properties

In the EU Cosmetics Regulation, there are no specific provisions addressing endocrine disruptors (ED) but a fitness check conducted by the European Commission (COM(2018)739) concluded that the tools foreseen in the Regulation are suitable to deal with potential health hazards connected with ED. In 2014, the EU Scientific Committee on Consumer Safety (SCCS) adopted a memorandum explaining the assessment process for potential ED. It also specified that the substances should be treated like other substances of concern for human health, therefore, be subject to risk assessment.

The objective of the poster is to present a stepwise ED assessment approach which considers the information derived from New Approach Methodologies (e.g., (Q)SAR, read across and in vitro assays). This approach is in line with the principles laid down in the OECD Conceptual Framework for the testing and assessment of endocrine disruptors and in the ECHA/EFSA 2018 guidance for the identification of EDs under the EU Biocides and Pesticides Regulation.

READ MORE ON THE PDF
Author
  • Ms. Sanghamitra Mishra

    Ms. Sanghamitra Mishra

  • Dr. Ankushreddy Patil

    Dr. Ankushreddy Patil

  • Mr. Pragnesh Panchamvedi

    Mr. Pragnesh Panchamvedi

  • Dr. Francesca Tencalla

    Dr. Francesca Tencalla

  • Dr. Thomas Petry

    Dr. Thomas Petry

MORE INSIGHTS
  • EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

  • The importance of having a solid PC data package to support human health/environmental risk assessment and read across under REACH

  • Using (Q)SAR and read across to evaluate the toxicological risks of data-poor drug impurities and extractables/leachables

EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

Previous thumb

Senior Toxicologist/Ecotoxicologist (Brussels based)

Scroll

 

ToxMinds are specialised in ensuring product safety and compliance.

We are passionate about toxicology and how emerging scientific developments can be utilised to support our customers in bringing safe, regulatory compliant and sustainable products to the marketplace.

 

 

 

 

Belgium
ToxMinds BVBA
Avenue de Broqueville 116
B-1200 Brussels, Belgium

VAT BE 0877.628.383

Tel: +32 (0)2 762 9145
Email: contact us

 

 

 

 

India
ToxMinds India Consulting Pvt. Ltd.
1015 Brigade IRV Centre, 10th Floor
Whitefield, Bangalore 560066, India

 

Email: contact us

 

 

 

 

 

LinkedIN
Copyright and disclaimer | Data privacy
  • Home
  • Industries
  • Services
  • Team
  • Insights
  • Work
  • Careers
  • Contact